Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline
Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.
Last updated: 2026-11-19 08:16:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ionis Pharmaceuticals, Inc. (IONS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27.39, with a market capitalization of $4.49B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $26.55 to $86.74. This page covers its latest market performance, valuation, price trends and company information.
$4.49B | |
$26.70 | |
$28.02 | |
$26.57 | |
$26.96 | |
2.39M | |
3.92M | |
-- | |
$86.74 | |
$26.55 | |
-- | |
2026-09-30 |
Ionis Pharmaceuticals, Inc. (IONS) last closed at $27.39 as of 2026-11-19 00:57:00, up 1.59% ($0.43) from the previous close of $26.96.
During the latest regular trading session, IONS traded between $26.57 and $28.02, with a volume of 2.39M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Ionis Pharmaceuticals, Inc. (IONS) moved from $28.19 to $27.39, representing a decline of 2.83% ($0.80).
The stock traded between $26.55 and $30.49 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 6.03 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.4%
IONS is currently trading at $27.39, placing it 1.4% of the way from its 52-week low of $26.55 to its 52-week high of $86.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1,402 |
| CEO | Brett P. Monia |
| Founded | 1989 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Ionis Pharmaceuticals, Inc. and IONS stock.
Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $65.
– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10
Eligible investors can buy real shares of Ionis Pharmaceuticals, Inc. (IONS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IONS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IONS shares and USD.
IONS Shares to USD
1.00 IONS shares = 27.392 USD
Calculations are estimates based on the latest available price and are for reference only.